Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Omeros Corporation
  6. Summary
    OMER   US6821431029

OMEROS CORPORATION

(OMER)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/19/2021 07/20/2021 07/21/2021 07/22/2021 07/23/2021 Date
13.83(c) 14.3(c) 14.37(c) 14.24(c) 14.19(c) Last
340 934 445 784 282 594 257 082 216 607 Volume
+1.69% +3.40% +0.49% -0.90% -0.35% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 107 M - -
Net income 2021 -128 M - -
Net Debt 2021 258 M - -
P/E ratio 2021 -7,15x
Yield 2021 -
Sales 2022 164 M - -
Net income 2022 -99,5 M - -
Net Debt 2022 239 M - -
P/E ratio 2022 -9,65x
Yield 2022 -
Capitalization 884 M 884 M -
EV / Sales 2021 10,6x
EV / Sales 2022 6,84x
Nbr of Employees 277
Free-Float 95,9%
More Financials
Company
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used... 
More about the company
Ratings of Omeros Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about OMEROS CORPORATION
06/18OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target
MT
06/16OMEROS : Form 8-K)
PU
06/16OMEROS CORP : Submission of Matters to a Vote of Security Holders, Financial Sta..
AQ
06/15OMEROS' : Narsoplimab pivotal trial data shared in oral presentation at 2021 ann..
AQ
06/14OMEROS : rsquo; Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 20..
BU
06/14Omeros Corporation Announces Narsoplimab Pivotal Trial Data in Oral Presentat..
CI
06/10OMEROS : Announces Publication Detailing the Mechanism of Action of PDE7 In Nico..
BU
06/09OMEROS : to Present at the BofA 2021 Napa BioPharma Virtual Conference
BU
06/09OMEROS : Says OMS906 Was Well-Tolerated in Phase 1 Trial in Alternative Pathway-..
MT
06/09OMEROS : Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
BU
06/09Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
CI
06/01SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investor..
PR
05/31OMEROS : Announces preliminary results from additional critically ill covid-19 p..
AQ
05/28OMEROS : Unveils Initial Results From Narsoplimab Treatment of Additional 'Criti..
MT
05/28OMEROS : Announces Preliminary Results from Additional Critically Ill COVID-19 P..
BU
More news
News in other languages on OMEROS CORPORATION
2019Principales informations avant-Bourse
2019Lonza coopère avec Omeros pour la commercialisation du Narsoplimab
More news
Analyst Recommendations on OMEROS CORPORATION
More recommendations
Chart OMEROS CORPORATION
Duration : Period :
Omeros Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEROS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 14,19 $
Average target price 27,00 $
Spread / Average Target 90,3%
EPS Revisions
Managers and Directors
Gregory A. Demopulos Chairman, President & Chief Executive Officer
Michael A. Jacobsen Chief Financial Officer, Treasurer & VP
George A. Gaitanaris Chief Scientific Officer & Vice President-Science
J. Steven Whitaker Chief Medical Officer & Vice President
Ray Aspiri Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OMEROS CORPORATION-0.67%973
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308